NANJING, China, July 15 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE:SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 second quarter results on Tuesday, August 5, 2008, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2008 second quarter results on Tuesday, August 5, at 8 a.m. EDT (Tuesday, August 5, at 8 p.m. Beijing/Hong Kong time).
To access the conference call, please dial: United States toll-free dial-in number: +1.866.510.0704
United States dial-in number: +1.617.597.5362
China toll-free dial-in number: 10.800.130.0399
Hong Kong dial-in number: +852.3002.1672 Please ask to be connected to Simcere's Q2 2008 Earnings Call and provide the following passcode: 25912661. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com/.
Following the earnings conference call, an archive of the call will be available by dialing: United States toll-free dial-in number: +1.888.286.8010
United States dial-in number: +1.617.801.6888 The passcode for replay participants is: 83949361. The telephone replay also will be archived on the "Investor Relations" section of the company's Web site at http://www.simcere.com/ for seven days following the earnings announcement.
About Simcere Pharmaceutical Group Simcere Pharmaceutical Group (NYSE:SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 39 principal pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com/.
For investor and media inquiries, please contact: Email: In Nanjing: Frank Zhigang Zhao
Chief Financial Officer
Simcere Pharmaceutical Group
Tel: +86-25-8556 6666 ext. 8818 In Beijing: Kejia Wu
Brunswick Group
Tel: +8610 6566 2256 In Hong Kong: Joseph Lo Chi-Lun
Brunswick Group
Tel: +852 3512 5000 In New York: Michael Guerin
Brunswick Group LLC
Tel: +1-212-333-3810
DATASOURCE: Simcere Pharmaceutical Group CONTACT: , or In Nanjing: Frank Zhigang Zhao, Chief Financial Officer, Simcere Pharmaceutical Group, +86-25-8556-6666 ext. 8818; In Beijing: Kejia Wu, +8610-6566-2256, or In Hong Kong: Joseph Lo Chi-Lun, +852-3512-5000, or In New York: Michael Guerin, +1-212-333-3810, all of Brunswick Group for Simcere Pharmaceutical Group Web site: http://www.simcere.com/
|